{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:01:33Z","timestamp":1777658493121,"version":"3.51.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":872,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Both acetazolamide and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors block sodium reabsorption in the proximal renal tubule primarily through inhibition of sodium\u2013hydrogen exchanger isoform 3 (NHE3), but neither SGLT2 inhibitors nor acetazolamide produce a sustained natriuresis due to compensatory upregulation of sodium reabsorption at distal nephron sites. Nevertheless, acetazolamide and SGLT2 inhibitors have been used as adjunctive therapy to loop diuretics in states where NHE3 is upregulated, e.g. acute heart failure. Two randomized controlled trials have been carried out with acetazolamide in acute heart failure (DIURESIS-CHF and ADVOR). In ADVOR, acetazolamide improved physical signs of fluid retention, but this finding could not be explained by the modest observed diuretic effect. Acetazolamide did not produce a natriuresis in the DIURESIS-CHF trial, and in ADVOR, immediate effects on symptoms and body weight were not reported, and the drug had no effect on morbidity or mortality after 90\u2009days. Three randomized controlled trials have been carried out with empagliflozin (EMPAG-HF, EMPA-RESPONSE-AHF and EMPULSE) in acute heart failure. The EMPULSE trial did not report effects on diuresis or in changes in physical signs of congestion during the first week of treatment, but in EMPAG-HF and EMPA-RESPONSE-AHF, empagliflozin had no effect of dyspnoea, urinary sodium excretion or body weight during the first 4\u2009days. In the EMPULSE trial, empagliflozin improved health status at 15\u2009days and reduced the risk of worsening heart failure events at 90\u2009days, but these effects are similar in magnitude and time course to the early statistical significance on the risk of heart failure hospitalizations achieved within 14\u201330\u2009days in the major trials of SGLT2 inhibitors in patients with chronic heart failure. Neurohormonal inhibitors produce this early effect in the absence of a diuresis. Additionally, in numerous randomized controlled trials, in-hospital diuretic intensification has not reduced the risk of major heart failure events, even when treatment is sustained. These findings, taken collectively, suggest that any immediate diuretic effects of acetazolamide and SGLT2 inhibitors in acute heart failure are not likely to influence the short- or long-term clinical course of patients.<\/jats:p>","DOI":"10.1002\/ejhf.2968","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T04:22:11Z","timestamp":1688530931000},"page":"1537-1543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Similarities and Distinctions Between Acetazolamide and Sodium\u2013Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSE"],"prefix":"10.1093","volume":"25","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[{"name":"Baylor University Medical Center , Dallas, TX ,","place":["USA"]},{"name":"Imperial College , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi School of Medicine , Jackson, MS ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2026010913100368300_ejhf2968-bib-0001","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913100368300_ejhf2968-bib-0002","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1681\/ASN.2020071029","article-title":"Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR, and restores euvolemia in nondiabetic rats with induced heart failure","volume":"32","author":"Borges-J\u00fanior","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026010913100368300_ejhf2968-bib-0003","doi-asserted-by":"crossref","first-page":"F383","DOI":"10.1152\/ajprenal.00464.2014","article-title":"Carbonic anhydrase II binds to and increases the activity of the epithelial sodium-proton exchanger, NHE3","volume":"309","author":"Krishnan","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026010913100368300_ejhf2968-bib-0004","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/dom.14769","article-title":"Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus","volume":"24","author":"Segar","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026010913100368300_ejhf2968-bib-0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/jcm8030349","article-title":"Acetazolamide therapy in patients with heart failure: A meta-analysis","volume":"8","author":"Wongboonsin","year":"2019","journal-title":"J Clin Med"},{"key":"2026010913100368300_ejhf2968-bib-0006","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026010913100368300_ejhf2968-bib-0007","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CRD.0b013e31822b4939","article-title":"Acetazolamide: A forgotten diuretic agent","volume":"19","author":"Kassamali","year":"2011","journal-title":"Cardiol Rev"},{"key":"2026010913100368300_ejhf2968-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026010913100368300_ejhf2968-bib-0009","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","article-title":"Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: A pilot study","volume":"37","author":"Imiela","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2026010913100368300_ejhf2968-bib-0010","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: Diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0011","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: The RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0012","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0013","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0014","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913100368300_ejhf2968-bib-0015","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jacc.2023.03.400","article-title":"Natriuretic response to acetazolamide in patients with acute heart failure and volume overload","volume":"81","author":"Verbrugge","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913100368300_ejhf2968-bib-0016","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2026010913100368300_ejhf2968-bib-0017","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: The CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913100368300_ejhf2968-bib-0018","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"2026010913100368300_ejhf2968-bib-0019","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026010913100368300_ejhf2968-bib-0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0021","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0023","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026010913100368300_ejhf2968-bib-0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913100368300_ejhf2968-bib-0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: Results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0026","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"2026010913100368300_ejhf2968-bib-0027","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010913100368300_ejhf2968-bib-0028","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: Data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13340-020-00474-2","article-title":"Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation","volume":"12","author":"Yamada","year":"2020","journal-title":"Diabetol Int"},{"key":"2026010913100368300_ejhf2968-bib-0030","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","author":"Packer","journal-title":"Eur Heart J"},{"key":"2026010913100368300_ejhf2968-bib-0031","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0032","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"7","author":"Vaduganathan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026010913100368300_ejhf2968-bib-0033","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0034","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/bcp.13505","article-title":"Effect of the angiotensin receptor-neprilysin inhibitor sacubitril\/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide","volume":"84","author":"Ayalasomayajula","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026010913100368300_ejhf2968-bib-0035","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"2026010913100368300_ejhf2968-bib-0036","doi-asserted-by":"crossref","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","article-title":"SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats","volume":"323","author":"Masuda","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026010913100368300_ejhf2968-bib-0037","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ekir.2022.02.023","article-title":"The adaptive renal response for volume homeostasis during 2\u2009weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet","volume":"7","author":"Scholtes","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026010913100368300_ejhf2968-bib-0038","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"key":"2026010913100368300_ejhf2968-bib-0039","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2022.01.019","article-title":"Relationship of dapagliflozin with serum sodium: Findings from the DAPA-HF trial","volume":"10","author":"Yeoh","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0040","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2681","article-title":"Renal effects of empagliflozin in patients hospitalized for acute heart failure: From the EMPULSE trial","volume":"24","author":"Voors","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913100368300_ejhf2968-bib-0041","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical Trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026010913100368300_ejhf2968-bib-0042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0043","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026010913100368300_ejhf2968-bib-0044","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1537\/65559732\/eurjhf_25_9_1537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1537\/65559732\/eurjhf_25_9_1537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:12:27Z","timestamp":1767982347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/9\/1537\/8341859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2968","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"2023-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}